Microsoft and Adaptive Biotechnologies' Immune System Partnership Takes on Coronavirus
The number of people diagnosed with COVID-19 continues to grow rapidly around the world, and while many companies are working on potential treatments and vaccines, there are still no approved therapies. With that said, it is worth noting that efforts to fight the novel coronavirus across a range of technologies continue to ramp up.
Image Source: Getty Images.
Back in January 2018, Microsoft (NASDAQ: MSFT) partnered with Adaptive Biotechnologies (NASDAQ: ADPT) -- a biotech company headquartered in Seattle, Washington -- to study how diseases affect the body's immune system. Specifically, they're attempting to map the T-cell receptors that immune cells develop to respond to specific signals of diseases (antigens).
Source Fool.com
